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Abstract Rectification of HERG is due to a rapid inactivation 
process that has been labeled C-type inactivation and is believed 
to be due to closure of the external mouth of the pore. We 
examined the effects of mutation of extracellular residues that 
remove C-type inactivation on binding of the intracellularly 
acting methanesulfonanilide drug E-4031. Removal of inactiva-
tion through mutation reduced drug affinity by more than an 
order of magnitude. Elevation of [K+]0 in the wild-type channel 
reduces channel affinity for E-4031. Elevation of [K+l0 also 
interferes with the extracellular pore mouth closure associated 
with C-type inactivation through a 'foot in the door' mechanism. 
We examined the possibility that [K"*"]0 elevation reduces drug 
binding through inhibition of C-type inactivation by comparing 
drug block in the wild-type and inactivation-removed mutant 
channels. Elevation of [K+|„ decreased affinity in both channel 
constructs by a roughly equal amount. These results suggest that 
|K+|0 alters drug binding affinity independently of its effects on 
C-type inactivation. They further suggest that inhibition of pore 
mouth closure by elevated |K+]0 does not have same effect on 
drug affinity as mutations removing C-type inactivation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
In cardiac myocytes, the rapid component of the delayed 
rectifier K+ channel (IKX) has been demonstrated to contribute 
to repolarization in cardiac muscle [1]. IKT activates more 
rapidly than the slow component of the delayed rectifier 
(IKS), shows strong inward rectification (IKI) [2,3], and is be-
lieved to have HERG (human ether-à-go-go related gene) as 
its molecular basis [4-6]. One unique feature of this channel is 
the specificity of its blockade by methanesulfonanilide drugs 
(e.g. E-4031 [1,2]), which has been exploited in the design of 
new antiarrhythmic drugs. Despite their selective action on 
this channel, little is understood about their mechanism of 
action. 
The strong inward rectification of HERG and IKI has re-
cently been proposed to result from a time-dependent inacti-
vation process [2,4,5,7,8]. This inactivation is insensitive to N-
terminal deletion and involves closure of the external mouth 
of the pore. Thus, inactivation of HERG has been attributed 
to a C-type mechanism [9]. However, inactivation of HERG 
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has some properties which are not traditionally associated 
with C-type inactivation and may be difficult to reconcile 
with a localized closure of the external mouth of the pore. 
In particular, inactivation has intrinsic voltage sensitivity 
[10,11]. The voltage sensitivity of inactivation results from 
movement of charge associated with conformational changes 
in membrane spanning domains. Such conformational 
changes are unlikely to be confined to the external mouth of 
the pore, but may be manifest through alteration of properties 
at the intracellular side of the channel. We therefore examined 
the effects of a mutation in the extracellular domains of 
HERG, which eliminates rapid inactivation, on kinetics, 
[K+]o sensitivity and binding of an intracellularly acting [12-
14] methanesulfonanilide compound, E-4031. Removal of C-
type inactivation in this channel greatly lowers affinity for E-
4031 and alters the voltage dependence of drug binding. 
2. Materials and methods 
Oocytes were voltage clamped using a two-microelectrode 'bath 
clamp' amplifier (OC-725A, Warner Instruments Corp., Hamden, 
CT) as has been described in detail elsewhere [15]. Microelectrodes 
were fabricated from 1.5 mm OD borosilicate glass tubing (TW150F-
4, WPI) using a two-stage puller (L/M-3P-A, Adams & List Associ-
ates, Ltd., Great Neck, NY), filled with 3 M KC1, and had resistances 
of 0.6-1.5 MQ. During recording, oocytes were continuously perfused 
with control ND 96 solution (in mM: 96 NaCl, 2 KC1, 1 MgCl2, 1.8 
CaCl2, 10 HEPES, pH = 7.4, adjusted with NaOH). 98 K solution 
contained (in mM): 98 KC1, 1 MgCl2, 1.8 CaCl2, 10 HEPES, 
pH = 7.4, adjusted with NaOH. Currents were recorded at room tem-
perature (21-23°C) and were filtered at 2.5 kHz for the two-electrode 
voltage clamp recordings. Data were recorded on video tape using an 
A/D VCR adaptor (model PCM 4/8, Medical Systems Corporation, 
Greenvale, NY) and digitized using 'pClamp' software (Axon Instru-
ments, Inc., Foster City, CA). Unless otherwise stated, raw two-elec-
trode voltage clamp data traces were not leakage or capacitance sub-
tracted. Defolliculated Xenopus laevis oocytes (stage V-VI) were 
injected with 50 nl cRNA solution prepared as described [15], con-
taining up to 50 ng HERG cRNA made from cDNA kindly provided 
by M. Keating, Univ. of Utah, Salt Lake City, UT. E-4031 was the 
generous gift of Esai Co. Ltd., Tsukuba Research Laboratories, Ja-
pan. Confidence levels were calculated using a paired i-test. 
3. Results 
The HERG channel has a six membrane spanning domain 
topology similar to other voltage gated channels similar from 
the Shaker family of potassium channels (Fig. 1). Despite a 
long intracellular N-terminal domain, this channel has been 
demonstrated to inactivate by C-type inactivation, or external 
pore mouth closure. Mutations in regions near the extracellu-
lar mouth of the pore have been shown to be involved in C-
type inactivation [9,16]. When residues at two positions indi-
cated in Fig. 1 are mutated to cysteines, C-type inactivation is 
removed in the mutant channel (HERG[GS:CC]) [9]. We 
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Fig. 1. Schematic diagram of the transmembrane spanning topology 
of the HERG channel showing the sites of the two point mutations 
at glycine-628 and serine-631. HERG channels show a six mem-
brane spanning domain topology similar to the Shaker family of 
K+ channels. S4 is thought to form the voltage sensor. The H5 
loop is thought to form the outer portion of the pore. The two mu-
tations introduced are shown. The resulting mutant construct 
HERG[GS:CC] lacks rapid C-type inactivation [9]. 
compared the properties of the WT channel with this mutant 
construct with respect to the [K+]0 and drug binding. 
Fig. 2A shows typical wild-type HERG currents recorded in 
response to a series of depolarizing PI pulses for 500 ms to 
potentials ranging between —80 and +50 mV followed by an 
500 ms P2 pulse to - 4 0 mV (Voiding = - 8 0 mV) in 2 mM 
[K+]0. These currents show the typical inward rectification 
characteristic of the HERG channel. HERG[GS:CC] shows 
no inward rectifying behavior (Fig. 2B) due to disruption of a 
rapid C-type inactivation mechanism as previously demon-
strated [9]. Previous studies have shown that C-type inactiva-
tion rate and steady-state C-type inactivation are altered in a 
destabilizing manner by elevation of [K+]0 [9-11,16]. The be-
havior of the WT channel and HERG[GS:CC] mutant chan-
nel in the presence of 98 mM [K+]0 is shown in Fig. 2C,D. 
Previous studies have shown that C-type inactivation inter-
feres with the binding of methanesulfonanilide drugs to the 
HERG channel [12-14]. This suggested that there was some 
interaction between intracellular binding of methanesulfona-
nilide drugs and C-type inactivation. In order to examine the 
molecular basis of this interaction, we measured the effect that 
the HERG[GS:CC] mutation had on the affinity of the chan-
nel for E-4031. E-4031 and the other methanesulfonanilide 
drugs which show specificity for I& are reported to be open 
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Fig. 2. Characteristics of HERG and HERG[GS:CC] mutant characteristics. A: Currents recorded from wild-type HERG expressed in Xenopus 
oocytes in the presence of 2 mM [K+]0. Oocytes were held at a clamp potential of —80 mV and stepped to potentials ranging between —80 
and +50 mV for 500 ms and then returned to —40 mV for 500 ms to elicit tail currents. Note that the tail currents are larger than the fully ac-
tivated currents at more positive potentials due to time-dependent inward rectification. B: Currents recorded from oocytes containing the muta-
tions G628C and S631C (designated HERG[GS:CC]), which have previously been shown to remove rapid C-type inactivation in HERG in the 
presence of 2 mM [K+]0. Note that time-dependent inward rectification is abolished and that the tail currents are much smaller than the fully 
activated currents. Oocytes were held at a clamp potential of —80 mV and stepped to potentials ranging between —80 and +50 mV for 500 ms 
and then returned to 0 mV for 500 ms to elicit tail currents. C: Currents recorded from wild-type HERG in the presence of 98 mM [K+]0. Oo-
cytes were held at a clamp potential of —80 mV and stepped to potentials ranging between —80 and +50 mV for 500 ms and then returned to 
—80 mV to elicit tail currents. D: Currents recorded from HERG[GS:CC] in the presence of 98 mM [K+]0 using the same protocol as in panel 
C. Oocytes were held at a clamp potential of —80 mV and stepped to potentials ranging between —80 and +50 mV for 500 ms and then re-
turned to —80 mV to elicit tail currents. 
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channel blockers and require channel activation in order for 
the drug to bind [12-14]. Drug binding is very slow and re-
quires special voltage clamp protocols for development of 
block [5,17]. We followed the example of Spector et al. [17] 
and allowed 10 min of perfusion time to allow equilibration of 
E-4031 across the membrane. After this wash-on period, a 
series of depolarizing pulses (from a holding potential of 
—80 mV to 0 mV for 400 ms at a frequency of 1 Hz for 
1 min) was applied, to elicit steady-state block. After this 
preconditioning protocol, steady-state block was measured 
from the degree of suppression of tail currents. As seen in 
Fig. 3A, application of 10 ¡J.M E-4031 resulted in almost com-
plete inhibition of the wild-type current. But 10 |xM E-4031 
resulted in only a partial block of the HERG[GS:CC] mutant 
channel (Fig. 3B). The overall dose-response curves for these 
two channel constructs shows that the mutation changed af-
finity for E-4031 by more than an order of magnitude (Fig. 
4A). The KB was shifted from 1.71 uM to 19.3 uM, demon-
strating that the binding affinity for this intracellularly acting 
compound was changed by an order of magnitude by the 
HERG[GS:CC] mutation. 
The change in drug affinity associated with the 
HERG[GS:CC] mutant suggested that C-type inactivation 
might itself be a determinant of drug binding properties. We 
tested this possibility using another manipulation that alters 
C-type inactivation through another mechanism, namely 
HERG (WT) 
50 r 
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3. 
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Fig. 4. Removal of C-type inactivation does not alter the [K+]0 de-
pendence of E-4031 binding. A: Dose-response curves showing the 
order of magnitude decrease in affinity of the HERG channel for E-
4031 following removal of C-type inactivation through mutation. B: 
Effects of [K+]0 on block of HERG and HERG[GS:CC]. The bar 
chart shows the percentage of control current in 2 mM and 98 mM 
[K+]0 in the presence of 1.71 |xM E-4031 for the HERG channel 
and 19.3 uM E-4031 for the HERG[GS:CC] mutant channel (* de-
notes statistical difference between [K+]0 groups P<0.05, n-4, 
paired i-test). Note that the fractional reduction of HERG and 
HERG[GS:CC] current shows nearly identical sensitivity to changes 
in [K+]0. 
B 
HERG [GS:CC] 
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Fig. 3. Block of HERG and HERG[GS:CC] by E-4031. A: Current 
traces showing the effects of fO uM E-4031 on the HERG channel. 
Both the outward current during a PI pulse to +50 mV and the re-
sulting tail currents were strongly blocked by this concentration of 
E-4031. B: Current traces showing the effects of the same concen-
tration (10 uM E-4031) on the HERG[GS:CC] mutant channel. In 
contrast to the effect on the WT channel, this concentration of E-
4031 only weakly blocked the channel. 
changing [K+]0. Changes in [K+]0 have been shown to influ-
ence drug binding to HERG [18]. C-type inactivation of 
HERG channels is sensitive to [K+]0 both in rate of develop-
ment [9,10,16] and in equilibrium [11] at any particular poten-
tial. If C-type inactivation conformational changes are impor-
tant in creating a high affinity binding site for E-4031, we 
would predict that elevation of [K+]0 would tend to reduce 
drug binding in the wild-type channel, while drug binding in 
the HERG[GS:CC] mutant channel would be unaffected by 
elevation of [K+]0. To test the effects of [K+]0 on drug affinity, 
we utilized a concentration of E-4031 that was near the KD for 
the WT and mutant channels (1.71 uM for WT channels and 
19.3 uM for mutant channels). Repeated pulses (from —80 
mV to 0 mV for 400 ms, 1 Hz, 1 min) were applied until 
block reached steady-state in both 2 and 98 mM [K+]0. Block 
was measured as suppression of peak tail currents at 0 mV for 
2 mM [K+]0 and - 8 0 mV for 98 mM [K+]0. As shown in Fig. 
4B the fractional inhibition of currents was [K+]0 sensitive for 
the WT channel with an average 32% decrease in total cur-
46 
rent. Surprisingly, the block of mutant channels showed a 
virtually identical sensitivity (34%) of block to [K+]0. 
4. Discussion 
Our data have shown that the HERG[GS:CC] mutation, 
which removes C-type inactivation through mutation of ex-
tracellularly facing residues, also strongly reduces affinity of 
this channel for E-4031. We also demonstrated that elevation 
of [K+]0 resulted in decreased affinity for E-4031 in the wild-
type channel. Since elevation of [K+]0 also destabilizes C-type 
inactivation [9,11], there were two potential mechanisms by 
which [K+]0 could be modulating drug binding affinity. One 
mechanism was direct interaction, e.g. through electrostatic 
repulsion or a 'knock-off process. The other mechanism 
would be indirect interaction through destabilization of the 
C-type inactivated conformation which favors drug binding. 
Had the second mechanism been important we would have 
expected that the HERG[GS:CC] mutant would have shown 
little change in affinity with elevation of [K+]0. Our results 
showed that the action of [K+]0 on drug binding was inde-
pendent of the presence of C-type inaction, suggesting that a 
direct interaction was dominant. 
Since both potassium and E-4031 carry a net single positive 
charge, electrostatic repulsion can provide a simple explana-
tion for the effects of potassium on E-4031 affinity. The cal-
culated affinity of E-4031 for wild-type HERG for shifts from 
1.71 to 3.63 mM when switching from 2 to 98 mM [K+]0. This 
corresponds to a reduction in the free-energy of drug binding 
of 0.44 kcal/mol. If an external binding site were 100% occu-
pied, the free energy change of binding due to the electrostatic 
force of repulsion between it and an intracellular positively 
charged drug could be calculated from the equation: 
AGelectrostatic = QlQ2/4TCe80d (1) 
where Qi and Q2 are the net charges on the permeant ion and 
drug, respectively, e is the dielectric constant, e0 is the polar-
izability of free space and d is the distance separating Qi and 
Q2. If we assume that the polarizability of a channel is similar 
to that of water (~80 [19]) and that when bound to the 
channel, both drug and externally bound permeant ion are 
approximately one bilayer thickness apart (2.3 nm [19]) then 
the maximal free energy of repulsion between an externally 
bound permeant ion and an intracellularly bound positively 
charged blocker is 3.2 kcal/mol. The conductance-activity re-
lationship of HERG macroscopic currents and the single 
channel conductance [K+]0 activity relationship of IKT are in-
dicative of a strong increase in ion occupancy between 2 and 
98 mM [K+]0. Therefore, the total free energy available from 
the binding of extracellular [K+]0 is sufficient to account for 
all of the observed reduction in drug sensitivity. 
Consideration of available free energy can also provide in-
sights into the role of pore mouth closure and C-type inacti-
vation in the drug-binding process. Elevation of [K+]0 from 
2 to 98 mM shifts the steady-state inactivation relation for 
HERG by an amount which is equivalent to 1.02 kcal/mol 
(calculated from [11]). This is also more than the 0.44 kcal/ 
mol change in the free energy of drug binding observed for 
the change in [K+]0. The preceding calculations demonstrated 
that there was sufficient free energy in both the potential elec-
trostatic interaction and in the modulation of Popen through 
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C-type inactivation to account for the [K+]0 modulation of 
drug binding. Thus, we initially anticipated that the free en-
ergy change in drug binding to the wild-type channel due to 
elevation of [K+]0 could be expressed as a sum of these two 
effects : 
AGwT.K = 0 .44 k c a l / m o l = AGDirect.electrostatic + AGindirect,C-type 
(2) 
where AGWT.K is the change in free energy of E-4031 drug 
binding observed when switching from 2 to 98 mM [K+]0. 
AGDirect,eiectrOStatic is the direct contribution of [K+]0 to this 
reduction in affinity due to electrostatic repulsion presumably, 
but also potentially due to interactions such as a 'knock-off 
mechanism or involving other conformational changes not 
directly resulting in closure of the extracellular mouth of the 
pore due to C-type inactivation. AG¡n(jirect,c-type is the ener-
getic contribution to the reduced affinity due to disruption of 
C-type inactivation in switching from 2 to 98 mM [K+]0. In 
the mutant channel, C-type inactivation is unavailable for 
modulation so AGilKjirect,c-type should be equal to zero. There-
fore, for the mutant channel Eq. 2 should simplify to: 
AGMT,K = 0 .39 k c a l / m o l = AGDirect.electrostatic (3) 
where AGMT.K is the change in free energy of E-4031 drug 
binding observed when switching from 2 to 98 mM [K+]0. 
Subject to the assumption that the mutation left 
AGDirect,eiectrostatic unchanged, the total change in free energy 
of drug binding that can be attributed to changes in the de-
velopment of C-type inactivation under these conditions can 
be estimated as the difference between Eqs. 2 and 3: 
AGindirect.c-type = AGWT,K-AGMT,K = 0.44-0.39 kcal/mol 
= 0.05 kcal/mol 
(4) 
which suggests that little, if any, of the free energy of drug 
binding is dependent on the external mouth of the pore clos-
ing during C-type inactivation. 
It has recently been suggested that many compounds show 
use dependence due to an ability to increase the rate of devel-
opment of C-type inactivation [20]. This is proposed to occur 
through a mechanism by which C-type inactivation is pro-
moted by decreased K+ occupancy of the pore associated 
with block of the channel and the associated decrease in K+ 
efflux through the pore [20]. This increase in the rate of devel-
opment of C-type inactivation seems unlikely to be the case 
for E-4031 block of HERG, since such a mechanism predicts 
a recovery from use-dependent block that parallels the rate of 
recovery from inactivation. Recovery from inactivation of 
HERG occurs in the order of 25 ms [11] and is far too fast 
to explain the use-dependent behavior shown for methanesul-
fonanilide drugs. Thus, simple promotion of C-type inactiva-
tion is not a viable explanation for the relationship between 
drug binding and the HERG[GS:CC] mutation. 
How, then, does the GS:CC mutation alter affinity at the 
binding site on the opposite side of the membrane? Direct 
changes in net charge on the membrane protein itself are 
possible but appear unlikely since the GS:CC mutation does 
not involve a change in charged side chains. Since these res-
idues also lie in the permeation pathway, it is also possible 
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that a binding site for permeant or impermeant (e.g. divalent) 
ions has been disrupted. However, the similarity in the ener-
getics of [K+]o on drug binding to the mutant and wild-type 
channel does not argue strongly for changes in the permeation 
pathway with the GS:CC mutation. Other data are difficult to 
reconcile with a the GS:CC mutation altering drug affinity 
purely through removal of extracellular pore mouth closure. 
WT HERG channels show decreasing rates of development of 
block with stronger depolarizations [12-14], a phenomenon 
which has been attributed to competition with C-type inacti-
vation [12-14]. In support of this hypothesis, we found that 
increasing depolarizations in mutant channels lacking C-type 
inactivation increased the rate of development of block in a 
fashion consistent with intracellular binding of a positively 
charged compound (data not shown). The GS:CC mutation 
data would seem to suggest a requirement for C-type inacti-
vation, while other data would seem to suggest that C-type 
inactivation interferes with drug binding at the intracellular 
side. These data are difficult to reconcile with a pure extra-
cellular pore-mouth closure mechanism. 
Another possible mechanism is that the GS:CC mutation 
changes the ability of the channel to form a high affinity 
binding conformation at the intracellular side of the pore. 
To date, the investigations into the mechanism of C-type in-
activation in Shaker K+ channels have implicated only fairly 
small rearrangements near the extracellular mouth of the pore 
[21]. It is not surprising, therefore, that C-type inactivation in 
Shaker and closely related channels shows little or no voltage 
dependence (e.g. [22,23]) as the superficial location of the res-
idues involved suggests that they would move through a small 
fraction of the total transmembrane electrical field. On the 
other hand, inactivation of HERG occurs with a strong volt-
age dependence, suggesting that a substantial transmembrane 
movement of charge occurs during this conformational 
change [11]. Such transmembrane movement is likely to alter 
intracellular as well as extracellular conformation. 
A body of evidence is slowly emerging that strongly sug-
gests that multiple conformational changes involving mem-
brane spanning domains occur in association with the phe-
nomenon of C-type inactivation. This study sheds some 
additional light on these conformational changes. Mutation 
of residues near the outer mouth of the pore strongly reduced 
the affinity of HERG for E-4031 at the intracellular side of 
the channel. However, simply stopping the development of C-
type inactivation in HERG through direct intervention via the 
'foot in the door' mechanism with 98 mM [K+]0 was not 
sufficient to alter drug binding. Thus, the GS:CC mutation 
may have disrupted both external pore mouth closure and 
formation of an intracellular binding conformation for E4031. 
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